INDIGO Home University of Illinois at Urbana-Champaign logo uic building uic pavilion uic student center

Beneficial Effects of a Switch to a Lopinavir/ritonavir-Containing Regimen for Patients with Partial or No Immune Reconstitution with Highly Active Antiretroviral Therapy Despite Complete Viral Suppression

Show full item record

Bookmark or cite this item: http://hdl.handle.net/10027/8204

Files in this item

File Description Format
PDF aids.pdf (299KB) (no description provided) PDF
Title: Beneficial Effects of a Switch to a Lopinavir/ritonavir-Containing Regimen for Patients with Partial or No Immune Reconstitution with Highly Active Antiretroviral Therapy Despite Complete Viral Suppression
Author(s): Pitrak, D.L.; Estes, R.; Novak, R.M.; Linnares-Diaz, M.; Tschampa, J.M.
Subject(s): human immunodeficiency virus LPV/r patient regimen highly active antiretroviral therapy
Abstract: The purpose of this study was to determine if switching to an Lopinavir/ritonavir (LPV/r)-containing regimen resulted in greater immune reconstitution in patients with immunologic failure despite complete viral suppression with highly active antiretroviral therapy (HAART). Twenty patients with partial or no immune response to HAART despite viral suppression were enrolled. Ten were randomized to stay on their current regimen and 10 were randomized to LPV/r plus their current NRTI backbone. T cell subsets, ex vivo apoptosis, and the percent of circulating cells with detectable intracellular HIV-1 RNA were measured. The mean increase in CD4+ count at 6 months was 116/mm3 (172–288) for the LPV/r-containing arm versus 32/mm3 (264–296) for continuation regimens ( p=0.03). The number of patients with an increase ≥50 cells/mm3 was also greater in the LPV/r arm (7/9 versus 2/10, p¼0.01). This paralleled a decrease in ex vivo apoptosis of naive CD4þ T cells at 6 months (21.7–11.0% for the LPV/r arm versus 17.3–18.9% for the continuation arm, p=0.04) and memory cells (21.1–14.1% for LPV/r versus 20.2–17.9% for continuation arm, NSS). Switching patients to an LPV/r-containing regimen improved CD4+ counts in patients with prior immunologic failure, and this may be due to an effect of LPV/r on apoptosis.
Issue Date: 2011-06
Publisher: Mary Ann Liebert
Citation Info: Pitrak, D. L., Estes, R., Novak, R. M., Linnares-Diaz, M., & Tschampa, J. M. 2011. Beneficial effects of a switch to a lopinavir/ritonavir-containing regimen for patients with partial or no immune reconstitution with highly active antiretroviral therapy despite complete viral suppression. AIDS Research and Human Retroviruses, 27(6): 659-667. DOI: 10.1089/aid.2010.0230
Type: Article
Description: This is a copy of an article published in Aids Research and Human Retroviruses © 2011 [copyright Mary Ann Liebert, Inc.]; Aids Research and Human Retroviruses is available online at: http://www.liebertonline.com.
URI: http://hdl.handle.net/10027/8204
ISSN: 0889-2229
Sponsor: This study was supported as an investigator-initiated study by a grant from Abbott Laboratories, Abbott Park, IL.
Date Available in INDIGO: 2012-03-15
 

This item appears in the following Collection(s)

Show full item record

Statistics

Country Code Views
United States of America 138
China 21
United Kingdom 15
Japan 9
Germany 7

Browse

My Account

Information

Access Key